5-TFMO-DMT (5-(trifluoromethoxy)-DMT, 5-OCF3-DMT, 5-(trifluoromethoxy)-N,N-dimethyltryptamine) is a
psychedelictryptamine derivative related to drugs such as
5-MeO-DMT and
DMT (DMT). It acts as an
agonist at the
5-HT2A receptor with an EC50 of 127.2 nM.[1] It was shown to release serotonin (5-HT) from synaptosomal preparations, and to reduce immobility time in the forced-swim test in animal studies, suggesting that it might have
antidepressant activity.[1]
^
abWO 2022/235927, Kruegel AC, "NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS.", published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc..
5-TFMO-DMT (5-(trifluoromethoxy)-DMT, 5-OCF3-DMT, 5-(trifluoromethoxy)-N,N-dimethyltryptamine) is a
psychedelictryptamine derivative related to drugs such as
5-MeO-DMT and
DMT (DMT). It acts as an
agonist at the
5-HT2A receptor with an EC50 of 127.2 nM.[1] It was shown to release serotonin (5-HT) from synaptosomal preparations, and to reduce immobility time in the forced-swim test in animal studies, suggesting that it might have
antidepressant activity.[1]
^
abWO 2022/235927, Kruegel AC, "NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS.", published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc..